Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a meta-analysis
1 Department of Gerontology and Geriatrics, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang 110001, China
2 Department of Pharmacy, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang 110001, China
3 Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang 110001, China
Citation and License
Diagnostic Pathology 2013, 8:180 doi:10.1186/1746-1596-8-180Published: 31 October 2013
Recent epidemiological studies suggest that treatment with insulin may promote cancer growth. The present systematic review and meta-analysis of published observational studies was conducted to assess the risk of cancer during treatment with insulin.
Materials and methods
A compressive search was conducted through MEDLINE, PubMed, Web of Science, EMBASE, and Chinese Biomedical Literature databases (CBM). Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated with a random-effects model.
A total of four studies with one case-controls study and three cohort studies comparing the insulin therapy and colorectal cancer susceptibility were identified. When all four studies were analyzed, the summary RRs were 1.61 (95% CI = 1.18–1.35) in a random-effects model for individuals with insulin therapy, compared with individuals without insulin therapy, which suggests a statistically significant association between insulin use and colorectal cancer.
Our findings provides the evidence that insulin therapy may contribute to the risk of colorectal cancer.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9339731010859509 webcite